July 30, 2022
and S.-H.C.; Investigation, J.Y.P., S.-H.C., J.-W.C., M.-H.H., and M.-C.K.; Resources, M.-H.H.; Data curation, M.-H.H. of allergy. Nearly all (172, 94.5%) of the participants reported at least one AE. Saquinavir Mesylate The most common AE was muscle or joint pain (73.6%), followed by injection site pain (69.2%), fatigue (67.0%), chills (64.3%), fever (51.1%), and headache (42.9%). The use of acetaminophen was observed in 81.9% of the participants (Table 1). Table 1 Demographics and vaccine adverse event serological assays. = 148= 34= 162= 18 0.05. Abbreviations: ELISA, enzyme-linked immunosorbent assay; SD, standard deviation; AE, adverse event; SUM, sum of symptoms severity score; SoM, sum of multiplying each symptoms severity by the duration of symptoms. 3.2. Association between Demographics and Scores of Adverse Events The systemic and localized SUM/SoM showed significant differences by sex (= 0.001, 0.001, 0.004, and 0.006, respectively) but not by occupation (= 0.159, 0.763, and 0.626, respectively), except for a difference Saquinavir Mesylate in the systemic SoM between nurses and medical laboratory technologists (= 0.028). The association between demographics and AEs is presented in Table 2. The systemic SUM and SoM showed a moderate negative linear relationship by aging (coefficient = ?0.356 and ?0.305, 0.001 for all), whereas the localized SUM and SoM showed a weak negative linear relationship by aging Saquinavir Mesylate (coefficient = ?0.169 and ?0.160, = 0.023 and 0.031, respectively). Table 2 The association between demographics and vaccine adverse events. 0.05. Abbreviations: SUM, sum of symptoms severity score; SoM, sum of multiplying each symptoms severity by the duration of symptoms; SD, standard deviation. a Significant difference was shown between nurses and laboratory technologists. 3.3. NAb Positivity and Related Factors Of the total 182 samples, positive NAb was found in 148 (81.3%). Both the positive and negative results of NAb did not differ significantly with sex, age, and occupation (= 0.054, 0.784, and 0.124, respectively). Of the AE symptoms, participants with the following signs showed significantly more positive than negative NAb results: fever (55.4% vs. 32.4%; = 0.015), headache (46.6% vs. 26.5%; = 0.032), chills (68.9% vs. 44.1%; = 0.006), muscle/joint pain (77.7% vs. 55.9%; = 0.009), and fatigue (72.3% vs. 44.1%; = 0.002). However, NAb levels in patients with fever and headache were not different when we performed IgG ELISA (= 0.112 and 0.160). Saquinavir Mesylate A significantly greater proportion of vaccine Saquinavir Mesylate recipients in the NAb-positive group consumed acetaminophen than those in the NAb-negative group (= 0.017). The positive rate with sVNT significantly increased when systemic SUM and SoM were higher (= 0.004 and 0.010) but showed no difference in the localized SUM/SoM (= 0.199 and 0.122) for IgG ELISA (Table 1). NAb levels showed significant differences based on sex (= 0.038) but no significant difference based on occupation and age (= 0.761 and 0.227). The values of NAb increased significantly with higher systemic SUM/SoM (= 0.003 and Rabbit Polyclonal to OR52E2 0.006; Figure 1). However, no difference was found for the localized SUM/SoM (= 0.301 and 0.369). The IgG level showed a difference based on sex (= 0.009) but not based on occupation and age (= 0.508 and 0.230). IgG levels also increased with a higher systemic SUM/SoM (= 0.002 and 0.009; Figure 1), but no difference was observed in terms of localized SUM/SoM (= 0.194 and 0.162). Open in a separate window Figure 1 Antibody response by scores of systemic adverse events. (a) Values of surrogate virus neutralization test by systemic SUM; (b) values of surrogate virus neutralization test by systemic SoM; (c) values of Euroimmun IgG ELISA by systemic SUM; (d) values of Euroimmun IgG ELISA by systemic SoM. Abbreviations: ELISA, enzyme-linked immunosorbent assay; SUM, sum of symptoms severity score; SoM, sum of multiplying each symptoms severity by the duration of symptoms. 3.4. Antibody Values Using Two Commercial Kits Of the 180 samples, positive results were reported in 146 (81.1%) participants who were tested using sVNT kits and in 162 (90.0%) tested using IgG ELISA kits. When IgG ELISA results that were borderline or negative were categorized as negative results, the strength of agreement between the two assays was the highest ( = 0.602, 0.001; Table 3). The values between IgG ELISA and sVNT showed a strongly positive linear correlation (r = 0.882, R2 = 77.7%, 0.001; Figure.